Baird Maintains Underperform on Biogen, Raises Price Target to $290

Baird maintains Biogen (NASDAQ:BIIB) with a Underperform and raises the price target from $250 to $290.

Benzinga · 02/06/2020 14:05

Baird maintains Biogen (NASDAQ:BIIB) with a Underperform and raises the price target from $250 to $290.